Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
Axsome Therapeutics (AXSM) Reports Q2 Loss, Tops Revenue Estimates
09:11am, Monday, 05'th Aug 2024
Axsome Therapeutics (AXSM) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.30. This compares to loss of $1 per share a year ago.
Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
07:00am, Monday, 05'th Aug 2024
Total 2Q 2024 net product revenue of $87.2 million, representing 87% year-over-year growth Auvelity® 2Q 2024 net product sales of $65.0 million, representing 135% year-over-year growth Sunosi® 2Q 20
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
11:06am, Monday, 29'th Jul 2024
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Biotech Stocks to Bet On Bright Industry Prospects
10:45am, Monday, 29'th Jul 2024
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, S
7 Biotech Stocks to Keep on Your Clinical Radar
02:57pm, Tuesday, 23'rd Jul 2024
Initially, I had every intention to write a cookie-cutter assessment of intriguing biotech stocks; that is, I wanted to say that enterprises within this specialized healthcare field will always be rel
Axsome Therapeutics: Lots Of Moving Parts
04:06am, Tuesday, 23'rd Jul 2024
Today, we circle back to mid-cap biopharma Axsome Therapeutics, which has multiple potential catalysts on the horizon. The company has two approved products on the market and the potential to have six
Wall Street Analysts Predict a 49.36% Upside in Axsome (AXSM): Here's What You Should Know
10:56am, Thursday, 18'th Jul 2024
The mean of analysts' price targets for Axsome (AXSM) points to a 49.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
07:15am, Monday, 15'th Jul 2024
Vertex Pharmaceuticals and Axsome Therapeutics are moving toward key regulatory approvals. Thanks to solid tailwinds, both biotechs should handsomely reward investors over the long run.
The 3 Best Biotech Stocks to Buy in July 2024
02:14pm, Friday, 05'th Jul 2024
Investing in biotech can be pretty unpredictable. Biotech stocks are highly volatile, and picking carefully can be the difference between losing all your capital and making unimaginable profits.
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
10:01am, Thursday, 04'th Jul 2024
One of the critical components of the investing world is the proliferation and understanding of analyst predictions. That's because most retail investors prefer to research consumer information regard
Should You Buy This Sinking Stock on the Dip?
09:42am, Thursday, 27'th Jun 2024
Axsome Therapeutics was recently the target of an activist short seller. The allegations will impact the biotech's financials if they are true.
Why Axsome Therapeutics Stock Is Sinking Today
12:35pm, Tuesday, 11'th Jun 2024
A short-seller alleged that Axsome has deals with mail-order pharmacies that inflate its reported revenue. If these allegations are proven true, the company could have to eventually restate its revenu
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
07:35am, Wednesday, 05'th Jun 2024
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company developing and delivering novel therapies for the management of central nervo
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system
3 Of My Favorite Names On Wells Fargo's Biotech Buyout List
02:45pm, Wednesday, 29'th May 2024
Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and t
